<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330770</url>
  </required_header>
  <id_info>
    <org_study_id>MSA5</org_study_id>
    <nct_id>NCT02330770</nct_id>
  </id_info>
  <brief_title>Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration</brief_title>
  <official_title>Dual Trigger Versus Gonadotropin Releasing Hormone Agonist Trigger Combined With Luteal Human Chorionic Gonadotropin Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the reproductive outcomes of intracytoplasmic sperm injection (ICSI) cycles in
      women at risk of ovarian hyperstimulation syndrome (OHSS) subjected to gonadotropin releasing
      hormone (GnRH) antagonist protocol followed by trigger with concomitant GnRH agonist (GnRHa)
      and low-dose human chorionic gonadotropin (HCG) administration (dual trigger), GnRHa trigger
      with single luteal low-dose HCG or GnRHa trigger with multiple luteal low-doses HCG
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GnRH antagonist fixed protocol will be used for controlled ovarian hyperstimulation
      (COH). Transvaginal sonography (TVS) scan will be performed regularly for monitoring of the
      follicular growth (folliculometry). When there will be at least 3 leading follicles &gt; 18 mm
      in diameter, women will be randomized into 3 groups; group A (dual trigger group), group B
      (single low-dose HCG group) and group C (multiple low-doses HCG group). In group A, final
      oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation
      (Triptorelin) SC and 1500 IU of HCG preparation IM. In group B, final oocyte maturation will
      be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG
      will by administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval). In
      group C, final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC
      then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte
      retrieval. In all women, oocyte retrieval will be performed 34-36 hours after trigger and
      endometrial preparation for embryo transfer (ET) will be started on the day of oocyte
      retrieval by giving 400 mg vaginal natural progesterone supplement once daily plus 4 mg oral
      estradiol valerate once daily.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
    <description>Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of ET procedures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oocyte maturation rate</measure>
    <time_frame>On day of oocyte retrieval</time_frame>
    <description>Number of mature oocytes divided by the number of retrieved oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early OHSS</measure>
    <time_frame>Within 9 days of final triggering of oocyte maturation</time_frame>
    <description>Incidence of OHSS within 9 days of final triggering of oocyte maturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
    <description>Number of gestational sacs on TVS scan at 4-6 weeks after ET divided by the number of transferred embryos</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>12 weeks gestational age</time_frame>
    <description>Number of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Dual trigger group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trigger with concomitant GnRHa and HCG (single low-dose) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single low-dose HCG group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trigger with GnRHa then HCG (single low-dose) administration in luteal phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple low-doses HCG group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHa and HCG</intervention_name>
    <description>Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM</description>
    <arm_group_label>Dual trigger group</arm_group_label>
    <other_name>Decapeptyl and Pregnyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHa then HCG</intervention_name>
    <description>Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)</description>
    <arm_group_label>Single low-dose HCG group</arm_group_label>
    <other_name>Decapeptyl then Pregnyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHa then HCG</intervention_name>
    <description>Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval</description>
    <arm_group_label>Multiple low-doses HCG group</arm_group_label>
    <other_name>Decapeptyl then Pregnyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with
             pituitary downregulation by GnRH antagonist.

          -  Presence of risk for development of OHSS: 1) previous moderate or severe OHSS; 2) PCOS
             or polycystic ovary on ultrasound scan; 3) antral follicle count (AFC) &gt; 14 in both
             ovaries; 4) basal serum AMH level &gt; 3.36 ng/ml; 5) &gt; 14 follicles with diameter of â‰¥
             11 mm on the day of triggering of oocyte maturation; 6) E2 level &gt; 3000 pg/ml on the
             day of triggering of oocyte maturation.

        Exclusion Criteria:

          -  Age &lt; 20 years or &gt; 35 years.

          -  BMI &lt; 19 kg/m2 or &gt; 35 kg/m2.

          -  Moderate or severe endometriosis.

          -  Hydrosalpinx.

          -  Uterine abnormalities or myoma.

          -  Previous uterine surgery.

          -  Use of alternative techniques to minimize the risk of OHSS.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waleed El-refaie, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Badawy, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed S Abdelhafez, Dr</last_name>
    <phone>+201144523366</phone>
    <email>msabdelhafez@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fertility Care Unit (FCU) in Mansoura University Hospital</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed S Abdelhafez, Dr</last_name>
      <phone>+201144523366</phone>
      <email>msabdelhafez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private fertility care centers</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2015</study_first_submitted>
  <study_first_submitted_qc>January 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed Sayed Abdelhafez</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>GnRHa trigger</keyword>
  <keyword>Luteal phase support</keyword>
  <keyword>OHSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

